Abstract 3937
Background
Surgical resection is the only curative treatment for pancreatic cancer but is very invasive. It usually causes severe stress in patients and may cause pain and deterioration of quality of life (QOL). Patient-reported QOL data are essential for describing patient symptomatology and evaluating care to adequately manage symptoms. Here we evaluated changes in health-related QOL (HRQOL) and symptoms in pancreatic cancer patients after surgical intervention.
Methods
The institutional review board of our university approved this study (2012-1-403); patients provided written informed consent. A QOL questionnaire survey was administered preoperatively and at postoperative months 3, 6, and 12. We statistically evaluated the correlations between the Short Form 36 Health Survey version 2 (SF-36v2 Standard, Japanese), which measures HRQOL, and specific symptoms of hepatobiliary and pancreatic cancer, using data collected from 100 postoperative pancreatic cancer patients (subtotal stomach-preserving pancreatoduodenectomy (PD), 54 patients; distal pancreatectomy, 36 patients; total pancreatectomy (TP), 10 patients). Responses were analyzed by two-way ANOVA and Spearman’s correlation coefficient analysis; p < 0.05 was considered significant. All statistical analyses were performed using SPSS (ver. 21).
Results
QOL was lowest at 3 months postoperatively on many domains of the SF-36v2 and had gradually improved by 12 months postoperatively. At 3 months, physical functioning (PF) (p < 0.001) and role-physical (RP) (p < 0.01) were significantly reduced in PD and TP patients. Also, QOL deterioration on SF-36v2 domains was correlated with weight loss (PF, RP, vitality (VT), role-emotional (RE); p < 0.05), worse bowel control (PF, BP, VT, RE, mental health (MH); p < 0.01-0.05), indigestion (PF, RP, GH, VT, social functioning, RE, MH; p < 0.001-0.05), appetite loss (all domains; p < 0.001-0.01), fatigue (PF, RE, MH; p < 0.05), and inability to perform usual activities (all domains, p < 0.001).
Conclusions
QOL after pancreatectomy can be improved by nutrition management, treatment combinations for symptoms related to digestion and absorption, and treatment for subjective symptoms including fatigue.
Clinical trial identification
Editorial acknowledgement
Think Science KK.
Legal entity responsible for the study
The authors.
Funding
JSPS KAKENHI Grant Number JP16K07140.
Disclosure
F. Motoi: Speaker Bureau / Expert testimony: Taiho Pharma, Mylan Japan, Daichi-Sankyo. M. Unno: Research grant / Funding (self): Taiho Pharma, Chugai; Research grant / Funding (institution): Taiho Pharma, Pfizer, Takeda, Chugai, Yakult, Asahi-Kasei. All other authors have declared no conflicts of interest.
Resources from the same session
2671 - Luminal B breast cancer prognosis prediction by comprehensive analysis of Homeobox genes
Presenter: Ayako Nakashoji
Session: Poster Display session 3
Resources:
Abstract
2650 - Long non-coding RNA E2F4as promotes tumor progression and predicts patient prognosis in human ovarian cancer
Presenter: Sun-Ae Park
Session: Poster Display session 3
Resources:
Abstract
1462 - FGF19 promotes esophageal squamous cell carcinoma progression by inhibiting autophagy
Presenter: Lisha Ying
Session: Poster Display session 3
Resources:
Abstract
5787 - Proof of concept on the role of ex vivo lung cancer spheroids, cytokines expression and PBMCs profiling in monitoring disease history and response to treatments.
Presenter: Raimondo Di Liello
Session: Poster Display session 3
Resources:
Abstract
5253 - Circulating microRNAs related to DNA damage response as predictors of survival in metastatic non- small cell lung cancer patients treated with platinum-based chemotherapy
Presenter: Dimitris Mavroudis
Session: Poster Display session 3
Resources:
Abstract
5286 - Prognostic value of CTCs in advanced NSCLC patients treated with platinum-based chemotherapy
Presenter: Silvia Calabuig-Fariñas
Session: Poster Display session 3
Resources:
Abstract
5781 - Exosomes in NSCLC as a source of biomarkers
Presenter: Elena Duréndez
Session: Poster Display session 3
Resources:
Abstract
1447 - The role of Pim-1 in the development and progression of papillary thyroid carcinoma
Presenter: Xin Zhu
Session: Poster Display session 3
Resources:
Abstract
1323 - Development and Validation of a RNA-Seq Based Prognostic Signature in Neuroblastoma
Presenter: Jian-Guo Zhou
Session: Poster Display session 3
Resources:
Abstract
3290 - Identification of meningioma patients in high risk of tumor recurrence using microRNA profiling
Presenter: Josef Srovnal
Session: Poster Display session 3
Resources:
Abstract